The EED Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited pool of NCI-H1299 cells with targeted disruption of the EED gene, generating a polyclonal loss-of-function model. This population reflects edited-cell heterogeneity and is designed for robust PRC2 functional studies without clonal selection bias, suitable for epigenetic and cancer biology investigations.
NCI-H1299 is a p53-deficient non-small cell lung carcinoma epithelial line derived from a lymph node metastasis of lung adenocarcinoma. Its p53-null status and origin from an aggressive cancer type make it a widely used model for studying NSCLC biology, including therapeutic resistance and metastatic mechanisms. This background provides a clinically relevant system for examining PRC2-driven epigenetics in the context of compromised tumor suppression.
EED is a core PRC2 subunit that binds H3K27me3 and allosterically activates the methyltransferase EZH2, catalyzing the propagation of repressive H3K27me3 marks and transcriptional silencing. Key downstream targets include CDKN2A (p16INK4a), CDKN2B (p15INK4b), and the HOXA gene cluster. EED functions downstream of developmental signals such as Wnt and Notch and cell cycle regulation, and it forms complexes with EZH2, SUZ12, RBBP4/7, and AEBP2. Through these interactions, EED coordinates epigenetic maintenance of gene expression programs involved in stem cell biology and development.
In NCI-H1299 cells, EED knockout ablates PRC2 catalytic function, reducing H3K27me3 and derepressing tumor suppressors. This disruption in a p53-deficient lung adenocarcinoma background enables dissection of EED??s role in sustaining proliferation, evading senescence, and modulating drug sensitivity. The polyclonal model captures phenotypic diversity akin to tumor heterogeneity, allowing studies on how PRC2 loss influences cellular adaptation and oncogenic signaling.
Research applications include Western blotting for EED and H3K27me3, ChIP-qPCR to map H3K27me3 changes, RNA-seq for transcriptome profiling, and functional assays for proliferation, migration, invasion, and apoptosis. Drug sensitivity testing with EZH2 inhibitors can be performed to validate therapeutic targets. This model facilitates investigations into PRC2-mediated gene silencing, epigenetic plasticity, and lung cancer pathogenesis. For additional information, please contact Ascent Research.
